Heron Therapeutics, Inc. (HRTX) Expected to Announce Quarterly Sales of $8.49 Million
Equities analysts expect that Heron Therapeutics, Inc. (NASDAQ:HRTX) will report sales of $8.49 million for the current fiscal quarter, Zacks reports. Three analysts have provided estimates for Heron Therapeutics’ earnings, with the highest sales estimate coming in at $9.00 million and the lowest estimate coming in at $7.66 million. The business is scheduled to announce its next quarterly earnings report on Tuesday, November 14th.
On average, analysts expect that Heron Therapeutics will report full year sales of $8.49 million for the current fiscal year, with estimates ranging from $26.69 million to $29.90 million. For the next financial year, analysts expect that the firm will post sales of $69.45 million per share, with estimates ranging from $55.00 million to $83.90 million. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side research analysts that follow Heron Therapeutics.
Heron Therapeutics (NASDAQ:HRTX) last released its earnings results on Wednesday, August 9th. The biotechnology company reported ($0.80) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.90) by $0.10. The business had revenue of $8.51 million for the quarter, compared to analysts’ expectations of $4.53 million.
HRTX has been the topic of a number of recent research reports. Jefferies Group LLC reiterated a “buy” rating on shares of Heron Therapeutics in a research note on Wednesday, August 16th. Northland Securities initiated coverage on shares of Heron Therapeutics in a research note on Wednesday, September 27th. They set an “outperform” rating and a $40.00 price objective on the stock. Noble Financial reiterated a “buy” rating and set a $24.00 price objective on shares of Heron Therapeutics in a research note on Friday, October 6th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Heron Therapeutics in a research note on Monday, June 26th. Finally, Zacks Investment Research upgraded shares of Heron Therapeutics from a “hold” rating to a “buy” rating and set a $14.00 price objective on the stock in a research note on Wednesday, July 12th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and eleven have assigned a buy rating to the stock. Heron Therapeutics has an average rating of “Buy” and a consensus price target of $28.50.
Heron Therapeutics (NASDAQ HRTX) opened at 15.50 on Friday. The stock’s market capitalization is $839.14 million. Heron Therapeutics has a 12-month low of $12.21 and a 12-month high of $20.85. The stock’s 50 day moving average is $15.79 and its 200 day moving average is $15.20.
Large investors have recently bought and sold shares of the stock. Wells Fargo & Company MN lifted its position in Heron Therapeutics by 78.8% during the first quarter. Wells Fargo & Company MN now owns 39,579 shares of the biotechnology company’s stock valued at $595,000 after acquiring an additional 17,442 shares during the last quarter. Janus Henderson Group PLC purchased a new stake in Heron Therapeutics during the second quarter valued at approximately $78,134,000. FMR LLC lifted its position in Heron Therapeutics by 36.7% during the first quarter. FMR LLC now owns 8,030,880 shares of the biotechnology company’s stock valued at $120,464,000 after acquiring an additional 2,158,041 shares during the last quarter. Bank of New York Mellon Corp lifted its position in Heron Therapeutics by 7.4% during the second quarter. Bank of New York Mellon Corp now owns 204,857 shares of the biotechnology company’s stock valued at $2,837,000 after acquiring an additional 14,086 shares during the last quarter. Finally, Point72 Asset Management L.P. purchased a new stake in Heron Therapeutics during the first quarter valued at approximately $2,002,000.
Heron Therapeutics Company Profile
Heron Therapeutics, Inc is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Heron Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.